185 related articles for article (PubMed ID: 32087264)
1. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
[TBL] [Abstract][Full Text] [Related]
2. The encapsulation of β-lapachone in 2-hydroxypropyl-β-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach.
Cavalcanti IM; Mendonça EA; Lira MC; Honrato SB; Camara CA; Amorim RV; Mendes Filho J; Rabello MM; Hernandes MZ; Ayala AP; Santos-Magalhães NS
Eur J Pharm Sci; 2011 Oct; 44(3):332-40. PubMed ID: 21888967
[TBL] [Abstract][Full Text] [Related]
3. Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.
Wang F; Blanco E; Ai H; Boothman DA; Gao J
J Pharm Sci; 2006 Oct; 95(10):2309-19. PubMed ID: 16883563
[TBL] [Abstract][Full Text] [Related]
4. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
Dong Y; Chin SF; Blanco E; Bey EA; Kabbani W; Xie XJ; Bornmann WG; Boothman DA; Gao J
Clin Cancer Res; 2009 Jan; 15(1):131-9. PubMed ID: 19118040
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of α-Pinene in Delivery Systems Based on Liposomes and Cyclodextrins.
Hammoud Z; Kayouka M; Trifan A; Sieniawska E; Jemâa JMB; Elaissari A; Greige-Gerges H
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833931
[TBL] [Abstract][Full Text] [Related]
7. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.
Nasongkla N; Wiedmann AF; Bruening A; Beman M; Ray D; Bornmann WG; Boothman DA; Gao J
Pharm Res; 2003 Oct; 20(10):1626-33. PubMed ID: 14620518
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
Jeong SY; Park SJ; Yoon SM; Jung J; Woo HN; Yi SL; Song SY; Park HJ; Kim C; Lee JS; Lee JS; Choi EK
J Control Release; 2009 Nov; 139(3):239-45. PubMed ID: 19619590
[TBL] [Abstract][Full Text] [Related]
10. Supramolecular interactions between β-lapachone with cyclodextrins studied using isothermal titration calorimetry and molecular modeling.
Xavier-Junior FH; Rabello MM; Hernandes MZ; Dias MES; Andrada OHMS; Bezerra BP; Ayala AP; Santos-Magalhães NS
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28675505
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
12. β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Zhang L; Chen Z; Yang K; Liu C; Gao J; Qian F
Mol Pharm; 2015 Nov; 12(11):3999-4010. PubMed ID: 26415823
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome.
Wang X; Deng L; Cai L; Zhang X; Zheng H; Deng C; Duan X; Zhao X; Wei Y; Chen L
J Pharm Sci; 2011 Aug; 100(8):3357-3364. PubMed ID: 21387317
[TBL] [Abstract][Full Text] [Related]
14. Integrity of liposomes in presence of cyclodextrins: effect of liposome type and lipid composition.
Hatzi P; Mourtas S; Klepetsanis PG; Antimisiaris SG
Int J Pharm; 2007 Mar; 333(1-2):167-76. PubMed ID: 17101248
[TBL] [Abstract][Full Text] [Related]
15. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.
Planchon SM; Pink JJ; Tagliarino C; Bornmann WG; Varnes ME; Boothman DA
Exp Cell Res; 2001 Jul; 267(1):95-106. PubMed ID: 11412042
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Characterization of Liposomes Double-loaded with Amphotericin B and Amphotericin B/hydroxypropyl-beta-cyclodextrin Inclusion Complex.
Tran THY; Vu TTG; Pham TMH
Pharm Nanotechnol; 2021; 9(3):236-244. PubMed ID: 33745428
[TBL] [Abstract][Full Text] [Related]
17. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
18. Drug-in-hydroxypropyl-β-cyclodextrin-in-lipoid S100/cholesterol liposomes: Effect of the characteristics of essential oil components on their encapsulation and release.
Hammoud Z; Gharib R; Fourmentin S; Elaissari A; Greige-Gerges H
Int J Pharm; 2020 Apr; 579():119151. PubMed ID: 32070761
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel/hydroxypropyl-β-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy.
Shen Q; Shen Y; Jin F; Du YZ; Ying XY
J Liposome Res; 2020 Mar; 30(1):12-20. PubMed ID: 30741058
[TBL] [Abstract][Full Text] [Related]
20. Cyclodextrins: Efficient biocompatible solubilizing excipients for bromhexine liquid and semi-solid drug delivery systems.
Stojanov M; Nielsen HM; Larsen KL
Int J Pharm; 2012 Jan; 422(1-2):349-55. PubMed ID: 22027391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
